Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Common Equity (2021 - 2025)

Kezar Life Sciences' Common Equity history spans 5 years, with the latest figure at $83.0 million for Q3 2025.

  • For Q3 2025, Common Equity fell 38.1% year-over-year to $83.0 million; the TTM value through Sep 2025 reached $83.0 million, down 38.1%, while the annual FY2024 figure was $116.9 million, 37.67% down from the prior year.
  • Common Equity for Q3 2025 was $83.0 million at Kezar Life Sciences, down from $91.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $297.4 million in Q2 2022 and bottomed at $83.0 million in Q3 2025.
  • The 5-year median for Common Equity is $169.1 million (2024), against an average of $179.3 million.
  • The largest annual shift saw Common Equity skyrocketed 137.02% in 2022 before it plummeted 39.09% in 2025.
  • A 5-year view of Common Equity shows it stood at $196.9 million in 2021, then skyrocketed by 37.08% to $269.9 million in 2022, then plummeted by 30.5% to $187.6 million in 2023, then crashed by 37.67% to $116.9 million in 2024, then decreased by 29.03% to $83.0 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Common Equity are $83.0 million (Q3 2025), $91.8 million (Q2 2025), and $103.1 million (Q1 2025).